BioPharmX (BPMX) Expects Topline Results from Phase 2b Trial of BPX-01 in First Half of May 2017
Tweet Send to a Friend
BioPharmX Corporation (NYSE: BPMX), a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE